Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENALTY: Keytruda in PML
NCT06276504Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in progressive multifocal leukoencephalopathy (PML), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
03
Conditions
progressive multifocal leukoencephalopathy (PML)
Beyond the preview
Go deeper on NCT06276504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06276504.